These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aducanumab: The first targeted Alzheimer's therapy. Yang P; Sun F Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067 [TBL] [Abstract][Full Text] [Related]
4. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220 [TBL] [Abstract][Full Text] [Related]
5. Amyloid-beta immunotherapy for Alzheimer's disease. Fu HJ; Liu B; Frost JL; Lemere CA CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Li Y; Liu Y; Wang Z; Jiang Y Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611 [TBL] [Abstract][Full Text] [Related]
7. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. Mukhopadhyay S; Banerjee D J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359 [TBL] [Abstract][Full Text] [Related]
8. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Høilund-Carlsen PF; Alavi A J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's. Song T; Wang Y; Silverglate BD; Grossberg GT Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223 [TBL] [Abstract][Full Text] [Related]
10. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers? Piazza F; Winblad B J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492 [TBL] [Abstract][Full Text] [Related]
11. Alternative Abeta immunotherapy approaches for Alzheimer's disease. Town T CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932 [TBL] [Abstract][Full Text] [Related]
12. Aducanumab: First Approval. Dhillon S Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167 [TBL] [Abstract][Full Text] [Related]
13. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease. Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910 [TBL] [Abstract][Full Text] [Related]
14. Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Marsool MDM; Prajjwal P; Reddy YB; Marsool ADM; Lam JR; Nandwana V Dis Mon; 2023 May; 69(5):101547. PubMed ID: 36931947 [TBL] [Abstract][Full Text] [Related]
15. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle. Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697 [TBL] [Abstract][Full Text] [Related]
16. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein. Parums DV Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135 [TBL] [Abstract][Full Text] [Related]
17. Aducanumab and the "post-amyloid" era of Alzheimer research? Musiek ES; Bennett DA Neuron; 2021 Oct; 109(19):3045-3047. PubMed ID: 34582783 [No Abstract] [Full Text] [Related]
18. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing? Cedernaes J; Schiöth HB; Benedict C Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192 [TBL] [Abstract][Full Text] [Related]